RT Journal Article
SR Electronic
T1 Early Diagnosis and Prognostic Prediction of Colorectal Cancer through Plasma Methylation Regions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.28.24317652
DO 10.1101/2024.11.28.24317652
A1 Zhu, Lingqin
A1 Yang, Lang
A1 Men, Fangli
A1 Yu, Jianwei
A1 Sun, Shuyang
A1 Li, Chenguang
A1 Ma, Xianzong
A1 Xu, Junfeng
A1 Li, Yangjie
A1 Tian, Ju
A1 Wang, Xin
A1 Xie, Hui
A1 Kang, Qian
A1 Duan, Linghui
A1 Yi, Xiang
A1 Guo, Wei
A1 Gong, Xueqing
A1 Guo, Ni
A1 Lu, Youyong
A1 Leung, Joseph
A1 He, Yuqi
A1 Sheng, Jianqiu
YR 2024
UL http://medrxiv.org/content/early/2024/12/05/2024.11.28.24317652.abstract
AB The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there are no biomarkers that serve simultaneously for early diagnosis and prognostic prediction in CRC patients. Herein, we developed a plasma panel (27 DMRs, differential methylated regions) and validated its superior performance across CRC diagnosis and prognosis prediction in an independent cohort. We first conducted a preliminary screening of 119 CRC tissue samples to identify CRC-specific methylation features. Subsequently, a CRC-specific methylation panel was developed by further filtering 161 plasma samples. Then machine learning algorithms were applied to develop diagnosis and prognosis models using cfDNA samples from 51 CRC patients and 33 normal controls. The diagnosis model was tested in a cohort consisting of 30 CRC, 37 advanced adenoma (AA), and 14 healthy plasma samples, independently validated in a cohort consisting of 18 CRC, 91 NAA, 23 AA and 34 healthy plasma samples. In the tissue external validation cohort (GSE48684), the cfDNA methylation diagnosis model conducted with the panel, have the area under the curve (AUC) reached 0.983, and for the plasma cfDNA model in the external validation cohort, the sensitivities for NAA, AA and CRC 0 -Ⅱ are 48.4%. 52.2% and 66.7% respectively, with a specificity of 88%. Additionally, the panel was applied to patient staging and metastasis, performing well in predicting CRC distant metastasis (AUC = 0.955) and prognosis (AUC = 0.867). Using normal samples as control, the changes in methylation score in both tissue and plasma were consistent across different lesions, although the degree of alterations varied with severity. The methylation scores vary between paired tissue and blood samples, suggesting distinct mechanisms of migration from tumor tissue to blood for the 27 DMRs. Together, Our cfDNA methylation models based on 27 DMRs can identify different stages of CRC and predict metastasis and prognosis, ultimately enabling early intervention and risk stratification for CRC patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by grants from the National Natural Science Foundation of China (Grant no. 82273245), the Capital's Funds for Health Improvement and Research (Grant no. 2022-1-5082), and the Beijing Natural Science Foundation (Grant no. 7212107), Sponsored by Dongying City Natural Science Foundation (Grant no. 2023ZR026), Sponsored by Longyan City Science and Technology Plan Project (Grant no. 2022LYF17082).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Seventh Medical Center of PLA General Hospital gave ethical approval for this work (Approval No. 2016-70, 2020-78).The Ethics Committee of Dongying People's Hospital gave ethical approval for this work (Approval No. DYYW-2019-002-01). The Ethics Committee of the First Hospital of Longyan, Fujian Medical University gave ethical approval for this work (Approval No. 2021-k0001).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48684 https://portal.gdc.cancer.gov/projects/TCGA-READ